Institute of Nutrition and Functional Foods (INAF)
Québec, Quebec, G1V 0A6, Canada
NCT Number: NCT02462655
Familial hypercholesterolemia (FH) is an autosomal codominant single-gene disorder caused by mutations in the LDL receptor gene that disrupt the normal clearance of LDL particles from the plasma compartment. Heterozygous patients present a 2- to 3-fold raise in plasma LDL-cholesterol (C) concentrations, tendinous xanthomatosis and premature atherosclerotic coronary heart disease (CHD), usually occurring between the age of 35 and 55 years. Since the mid-1970s, LDL-C has been removed from the blood of patients using plasmapheresis, and this technique has been shown to improve the life expectancy of FH homozygotes. LDL apheresis selectively removes LDL particles but not immunoglobulins and other beneficial proteins, thereby overcoming a potential drawback of the traditional plasmapheresis method. LDL-C is effectively reduced by more than 60% immediately after LDL apheresis, although LDL levels rebound rapidly.
Dextran sulfate adsorption is a commonly apheresis technique used in familial hypercholesterolemia patients. In this apheresis plasma is separated from red blood cells and passed over columns of cellulose beads containing dextran sulfate which binds apolipoprotein B (apoB) by a highly selective electrostatic binding mechanism. Since LDL, very-low density lipoprotein (VLDL), and Lipoprotein (a) all contain apoB, dextran sulfate adsorption apheresis selectively reduces these lipoproteins while having little effect on the non-apoB containing HDL particles. In clinical practice, LDL apheresis reduces the rate of future cardiovascular events and has been postulated to have additional effects on potentially pro-atherogenic factors. Some proteins have been identified with adhesive characteristics to lipoproteins, rheological, immunological and inflammation relevant proteins16-19 that influence microcirculation as well as the inflammatory response. However, no studies have yet to investigate the impact of LDL apheresis on the expression of different genes involved in cardiovascular disease.
The main objective of the present research project is to investigate the impact of the LDL apheresis dextran sulfate adsorption system on the messenger ribonucleic acid (mRNA) expression of genes involved in cardiovascular disease using microarrays analysis in 9 FH homozygotes.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Québec, Quebec, G1V 0A6, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Blood samples will be taken just before the start of the lipid apheresis treatment.
Blood samples will be taken following the lipid apheresis treatment.
Time frame: Pre-lipid apheresis (t=0h) and post-lipid apheresis (t=3h)
Time frame: Pre-lipid apheresis (t=0h) and post-lipid apheresis (t=3h)
Time frame: Pre-lipid apheresis (t=0h) and post-lipid apheresis (t=3h)
Laval University
Other
Acronym: LA-PBMC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03140605
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Athens, Greece
View Trial DetailsNCT05218005
Acute Coronary Syndrome, Cardiovascular Diseases
Vancouver, British Columbia, Canada
View Trial DetailsNCT03832985
Adnexal Diseases, Breast Diseases
Danville, Pennsylvania, United States
View Trial DetailsNCT05952869
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Daphne, Alabama, United States
View Trial Details